Beam Therapeutics Inc. 8-K

What Happened

• Beam Therapeutics Inc. filed a Form 8-K on Jan 12, 2026 disclosing an estimate of approximately $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. The company noted it has not finalized full financial results for the fourth quarter and fiscal year ended Dec 31, 2025.
• The company also announced progress across its base editing portfolio in a press release dated Jan 11, 2026 and furnished an updated corporate presentation (slides) on Jan 12, 2026 to be used at investor and conference meetings, including its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026.

Key Details

• Estimated cash, cash equivalents and marketable securities: approximately $1.25 billion as of Dec 31, 2025.
• Press release announcing portfolio progress: dated Jan 11, 2026 (Exhibit 99.1).
• Corporate presentation updated and furnished: Jan 12, 2026, including slides for the JP Morgan Healthcare Conference on Jan 13, 2026 (Exhibit 99.2).
• Form 8-K signed by CEO John Evans on Jan 12, 2026.

Why It Matters

• Liquidity: The ~$1.25B cash estimate gives investors a snapshot of Beam’s available liquidity heading into 2026, which is a key input for assessing runway and funding for R&D and operations (full audited results for Q4/FY 2025 were not yet finalized).
• Investor visibility: The press release and updated corporate presentation provide management’s current view of program progress and near-term milestones, useful for evaluating clinical and development timelines.
• Near-term events: The updated slides and the company’s presentation at the JP Morgan conference may contain additional details investors will watch for when full quarterly and annual results are released.